KalVista Pharmaceuticals (KALV) Amortizatization of Intangibles (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Amortizatization of Intangibles of -$7000.0 in Q3 2025, down 333.33% quarter-over-quarter from $3000.0 in Q2 2025, and down 240.0% year-over-year from $5000.0 in Q3 2024.
KalVista Pharmaceuticals' Amortizatization of Intangibles history runs 10 years deep, the most recent figure standing at -$7000.0 for Q3 2025.
- In Q3 2025, Amortizatization of Intangibles fell 240.0% year-over-year to -$7000.0; the TTM figure through Jul 2025 stood at $6000.0 (down 82.86% YoY), while the FY2025 annual figure was $14000.0, down 84.78% from the prior year.
- Amortizatization of Intangibles came in at -$7000.0 for Q3 2025 at KalVista Pharmaceuticals, down from $3000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $753000.0 in Q3 2021 to a low of -$7000.0 in Q3 2025.
- A 5-year average of $233277.8 and a median of $104000.0 in 2021 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles surged 1007.35% in 2021 and tumbled 240.0% in 2025, its largest moves.
- KalVista Pharmaceuticals' Amortizatization of Intangibles stood at $671000.0 in 2021, then sank by 57.23% to $287000.0 in 2022, then plunged by 92.68% to $21000.0 in 2023, then slumped by 76.19% to $5000.0 in 2024, then sank by 240.0% to -$7000.0 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$7000.0, $3000.0, and $5000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -7,000.00 |
| Jul 31, 2025 | -7,000.00 |
| Apr 30, 2025 | 3,000.00 |
| Apr 30, 2025 | 3,000.00 |
| Oct 31, 2024 | 5,000.00 |
| Oct 31, 2024 | 5,000.00 |
| Jul 31, 2024 | 5,000.00 |
| Jul 31, 2024 | 5,000.00 |
| Apr 30, 2024 | 4,000.00 |
| Apr 30, 2024 | 4,000.00 |
| Jan 31, 2024 | 5,000.00 |
| Jan 31, 2024 | 5,000.00 |
| Oct 31, 2023 | 21,000.00 |
| Oct 31, 2023 | 21,000.00 |
| Jul 31, 2023 | 62,000.00 |
| Jul 31, 2023 | 62,000.00 |
| Apr 30, 2023 | 98,000.00 |
| Apr 30, 2023 | 98,000.00 |
| Jan 31, 2023 | 212,000.00 |
| Jan 31, 2023 | 212,000.00 |
| Oct 31, 2022 | 287,000.00 |
| Oct 31, 2022 | 287,000.00 |
| Jul 31, 2022 | 391,000.00 |
| Jul 31, 2022 | 391,000.00 |
| Apr 30, 2022 | 484,000.00 |
| Apr 30, 2022 | 484,000.00 |
| Jan 31, 2022 | 657,000.00 |
| Jan 31, 2022 | 657,000.00 |
| Oct 31, 2021 | 671,000.00 |
| Oct 31, 2021 | 671,000.00 |
| Jul 31, 2021 | 753,000.00 |
| Jul 31, 2021 | 753,000.00 |
| Apr 30, 2021 | 438,000.00 |
| Apr 30, 2021 | 438,000.00 |
| Jan 31, 2021 | 110,000.00 |
| Jan 31, 2021 | 110,000.00 |
| Oct 31, 2020 | 69,000.00 |
| Oct 31, 2020 | 69,000.00 |
| Jul 31, 2020 | 68,000.00 |
| Jul 31, 2020 | 68,000.00 |
| Apr 30, 2020 | 57,000.00 |
| Apr 30, 2020 | 57,000.00 |
| Jan 31, 2020 | 57,000.00 |
| Jan 31, 2020 | 57,000.00 |
| Oct 31, 2019 | 44,000.00 |
| Oct 31, 2019 | 44,000.00 |
| Jul 31, 2019 | 35,000.00 |
| Jul 31, 2019 | 35,000.00 |
| Mar 31, 2016 | 7,000.00 |
| Mar 31, 2016 | 7,000.00 |
| Dec 31, 2015 | 7,000.00 |
| Dec 31, 2015 | 7,000.00 |
| Sep 30, 2015 | 15,000.00 |
| Sep 30, 2015 | 15,000.00 |
| Jun 30, 2015 | 51,000.00 |
| Jun 30, 2015 | 51,000.00 |
| Mar 31, 2015 | 707,000.00 |
| Mar 31, 2015 | 707,000.00 |
| Mar 31, 2014 | 48,000.00 |
| Mar 31, 2014 | 48,000.00 |